Impact BioMedical, INC. Proceeds from Issuance of Debt
Impact BioMedical, INC. (IBO) reported Proceeds from Issuance of Debt of $2.19 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2025-03-28
- Impact BioMedical, INC. proceeds from issuance of debt for the quarter ending 2024-12-31 was $587.00K, a 153.02% increase year-over-year.
- Impact BioMedical, INC. proceeds from issuance of debt for the quarter ending 2024-09-30 was $224.00K, a 74.25% decline year-over-year.
- Impact BioMedical, INC. proceeds from issuance of debt for the quarter ending 2023-12-31 was $232.00K.
- Impact BioMedical, INC. proceeds from issuance of debt for the quarter ending 2023-09-30 was $870.00K.
- Impact BioMedical, INC. proceeds from issuance of debt for fiscal 2024 was $2.19M, a 23.60% decline from fiscal 2023.
- Impact BioMedical, INC. proceeds from issuance of debt for fiscal 2023 was $2.87M.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $587.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $811.00K derived: sum of 2 quarters · filed 2025-03-28 | $2.19M 10-K · filed 2025-03-28 | |
| 2024-09-30 | $224.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.60M 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $1.38M 10-Q · filed 2024-08-13 | |||
| 2023-12-31 | $232.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $1.10M derived: sum of 2 quarters · filed 2025-03-28 | $2.87M 10-K · filed 2025-03-28 | |
| 2023-09-30 | $870.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.63M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $1.76M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |